Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.11.18 (
MAP
)
7,412
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
H-rev107-1 is a growth inhibitory RAS target gene capable of suppressing anchorage independent growth in vitro and in vivo. Using a tumour tissue array with 241 matched tumour and normal tissue cDNA pools, we found down-regulation of
H-REV107-1
in 7 out of 14 ovary-derived cDNAs. RT-PCR analysis and immunohistochemical investigation confirmed expression of
H-REV107-1
in normal ovarian epithelial cells but down-regulation in high grade ovarian carcinomas.
H-REV107-1
is also strongly expressed in immortalized rat and human ovarian epithelial cells in vitro, but suppressed in transformed cells by two different mechanisms. KRAS-transformed rat ovarian cells and PA1 teratocarcinoma cells, reversibly repress
H-REV107-1
via
MAP
/ERK signaling. In contrast, treatment of A27/80 and OVCAR-3 epithelial ovarian cancer cells with IFNgamma stimulated
H-REV107-1
expression. In NIH3T3 cells harbouring an estrogen-inducible IRF-1, H-rev107-1 is directly induced after activation of IRF-1, indicating that H-rev107-1 is a target of IRF-1. Stimulation of
H-REV107-1
expression was also observed in ovarian epithelial cells suggesting that IRF-1 is involved in
H-REV107-1
regulation in human ovarian epithelium. In the IFNgamma-sensitive cell line A27/80,
H-REV107-1
suppresses colony formation. A27/80 and OVCAR-3 cells overexpressing
H-REV107-1
protein underwent apoptosis. These results demonstrate down-regulation of the class II tumour suppressor
H-REV107-1
in human ovarian carcinomas and suggest an involvement of
H-REV107-1
in interferon-dependent cell death.
...
PMID:The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. 1197 42
